Biotech, Food, Drug

The food we eat and the medicine we put into our bodies are highly regulated by a variety of government agencies. In the United States by the Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA) regulate the processes by which food makes its way to the grocery store and medicine is approved for consumer use.  As the science grows more complex behind the pharmaceutical and food industry, interpretation of the regulations in place is becoming more nuanced.  Overseas, these industries are regulated by a variety of agencies; for example, the Minister of Agriculture in Canada, Centre for Food Safety in Hong Kong, and the Committee of Environmental, Public Health and Food Safety (EU), are among the many governing-bodies which regulate biotechnology, food, and drugs throughout the world.

The National Law Review is your free online resource to agency news, emerging topics in food and drug, and the latest in biotechnology updates. From nanotechnologies being used in research, to regulations of imported foods coming into the US from overseas or the development of medical devices and drugs, readers can find expert legal analysis of the developments in the industry, as well as reports on changes within the agencies that regulate these industries. The National Law Review also covers topics related to licensing, Food Safety and Inspection Services (FSIS), food and beverage regulation in the US and worldwide, nutrition labeling, and country of origin labeling guidelines.

With recent legislation being passed throughout the US in relation to marijuana use, both for recreational and medicinal purposes, readers will also find up-to-date information, litigation, and news coming from this area of interest as well. Regulations in California for labeling and proper sales of marijuana, to use in different states, or internationally, as well as rules for promoting and advertising marijuana are also covered on the site. Additionally, the development and changing landscape of tobacco use to include vaping, and how e-cigarettes and vaping are regulated, is also covered by NLR authors.

Readers who are interested in food safety, inspection, imports into the US, and regulations, these topics are covered regularly on The National Law Review as well. New legislation from the FDA, USDA, Department of Agriculture, and international bodies, are covered on the site. If you are looking for details on new nutrition-labeling regulations or health risks of consuming certain imported foods, you will find these topics, and many more, on The National Law Review.

For hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis Twitter feed, and sign up for complimentary e-news bulletins.

Custom text Title Organization Sort descending
Apr
26
2023
The Legal Battle Over Mifepristone Epstein Becker & Green, P.C.
Nov
22
2019
Limitations on Pre-Employment Testing for Marijuana Epstein Becker & Green, P.C.
Feb
2
2016
FDA Recommends Medical Device Manufacturers Implement a Comprehensive Cybersecurity Risk Management Program in Accordance with NIST Standards Epstein Becker & Green, P.C.
Aug
8
2023
The FTC Finalizes Changes to Endorsement Guides Epstein Becker & Green, P.C.
Aug
23
2023
SuperValu’s Effect on the FCA Scienter Standard and Impact to Future Litigation Epstein Becker & Green, P.C.
Sep
5
2023
Unpacking Averages: How Accurate Do Class II Medical Devices Need to Be to Obtain 510(k) Clearance? Epstein Becker & Green, P.C.
Mar
19
2020
FDA Issues Guidance for Ongoing Clinical Trials During COVID-19 Pandemic Epstein Becker & Green, P.C.
Apr
28
2020
Face or Fingerprint? The DEA Revisits Biometric Identifiers for e-Prescribing Controlled Substances Epstein Becker & Green, P.C.
Jan
19
2024
Sponsored Genetic Testing Programs: Compliance Considerations Following DOJ False Claims Act Settlement Epstein Becker & Green, P.C.
Aug
18
2021
How Can Companies in the Health Care and Life Sciences Industries Strengthen Their Cybersecurity Posture? [PODCAST] Epstein Becker & Green, P.C.
Apr
3
2019
FDA Commissioner Gottlieb Says Agency Will Not Tolerate Deceptive Marketing of CBD Products; Issues Warning Letters Epstein Becker & Green, P.C.
Oct
13
2022
Four Years After EKRA: Reminders for Clinical Laboratories Epstein Becker & Green, P.C.
Mar
1
2023
Unpacking Averages: Exploring New Data on FDA Responses to FOIA Requests Epstein Becker & Green, P.C.
Apr
4
2023
Is CMS Ignoring the Realities of Biopharmaceutical Costs? Epstein Becker & Green, P.C.
Aug
1
2023
Unpacking Averages: Analyzing the Relationship Between MDRs and Recalls Epstein Becker & Green, P.C.
Sep
12
2023
HHS Recommends Re-Classification of Marijuana as a Schedule III Controlled Substance – A Bellwether for the Future of Cannabis-ness Epstein Becker & Green, P.C.
Mar
24
2020
Medical Marijuana Deemed “Essential” During COVID-19 Pandemic Epstein Becker & Green, P.C.
Mar
8
2024
BioMarin Subpoena Potentially Signals Continued Investigations into Sponsored Testing Programs Epstein Becker & Green, P.C.
Jan
10
2017
New Federal and State Initiatives Seek to Combat Antimicrobial Resistance Epstein Becker & Green, P.C.
Jun
7
2017
Growing Questions About Employee Medical Marijuana Use Leave Employers in a Haze Epstein Becker & Green, P.C.
Aug
18
2021
Vaccine Mandates, Mandate Bans, Wage and Hour Nomination Stalls – Employment Law This Week [VIDEO] Epstein Becker & Green, P.C.
Jan
13
2022
CMS “Splits the Baby” on Aduhelm—Medicare Coverage but Only with Evidence Development for Now Epstein Becker & Green, P.C.
Oct
23
2018
CMS Unveils Proposed Rule Regarding Direct-to-Consumer Television Advertisements for Prescription Drug and Biological Products Epstein Becker & Green, P.C.
Dec
18
2018
Mixed Results for Employers on Marijuana – Two Federal Courts Refuse to Find State Marijuana Laws Preempted by Federal Law Epstein Becker & Green, P.C.
May
20
2022
Recent FDA Enforcement Action Colors Regulatory Landscape for Delta-8 THC Products Epstein Becker & Green, P.C.
Jan
31
2023
FDA Issues Final and Draft Guidance Documents Regarding Food Allergen Labeling Epstein Becker & Green, P.C.
Aug
29
2019
Will the Growing Acceptance of Cannabis Send Drug-Screening Policies Up in Smoke? Epstein Becker & Green, P.C.
Dec
14
2023
President Seeks More Antitrust Scrutiny of Health Care Transactions Epstein Becker & Green, P.C.
Jun
4
2021
EEOC Updates Guidance on COVID-19 Vaccination Policies, Including Mandates, Incentives, and Accommodations Epstein Becker & Green, P.C.
Feb
16
2022
Employers Take Heed: Follow Illinois Biometric Privacy Rules or Risk a Losing Battle Epstein Becker & Green, P.C.
May
20
2022
The VALID Act: Senate Action Brings FDA Regulation of LDTs Closer to Fruition Epstein Becker & Green, P.C.
Feb
13
2019
CBD “Edibles” Face Opposition from States, FDA Epstein Becker & Green, P.C.
Feb
26
2019
FDA Finalizes Two Guidance Documents Regarding Regenerative Medicine Therapies Epstein Becker & Green, P.C.
Mar
10
2015
3-D Printing Guidance Only a B-List Priority for FDA Epstein Becker & Green, P.C.
Jul
18
2019
Hawaii Decriminalizes Possession of Small Amounts of Marijuana Epstein Becker & Green, P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins